Clinical Trial Update: Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of ibrutinib with/without obinutuzumab +/- CHOP for Richter's Transformation/Richter's Syndrome was terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Richter Syndrome

Drugs mentioned

• Ibrutinib (ibrutinib)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Northwell Health | Conditions: Richter Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2023-06-01